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Abstract
The first 15 years of the human immunodeficiency virus type 1 epidemic was characterized by
patients progressing to clinical acquired immunodeficiency syndrome and death. The availability of
potent antiretrovirals led to the recognition of unique adverse events associated with select drugs.
More recent data suggest that end-organ damage may be associated with ongoing viremia. Further
understanding of the potential role different drugs and the virus itself has on various organs can
enhance the clinician’s ability to manage patients in the clinic.
Introduction and context
Prior to the availability of potent antiretroviral (ARV)
therapy, human immunodeficiency virus type 1 (HIV-1)
infection was notable for the inevitable progression to
acquired immunodeficiency syndrome (AIDS)-defining
events and death. With the advent of mono- and dual-
nucleoside reverse transcriptase inhibitor (NRTI) therapy,
there was recognition of diverse drug-related adverse
events. The introduction of combination ARV therapy
with dual NRTIs plus protease inhibitors (PIs) was
associated with a dramatic decline in AIDS and mortality,
along with an increased appreciation for the development
of diverse metabolic complications, such as insulin
resistance and dyslipidemia,as well as more recent reports
actually showing evidence of premature cardiovascular
disease [1]. In addition, co-morbid conditions such as
renal and hepatic disease increasingly influenced the
quality of the lives of HIV-1-infected individuals. Over
the ensuing years research has attempted to define the
potential role that select ARV agents and HIV-1 infection
itself have on hepatic, renal, and cardiovascular disease.
Recent advances
Cardiovascular disease
Numerous factors are known to be associated with
increased risk of atherosclerotic disease, such as diabetes
mellitus, hypertension, smoking, family history and
dyslipidemia, all of which occur with variable frequency
in those with HIV-1 infection. As combination ARV
therapy allowed HIV-1-infected individuals to live
longer, these common causes of mortality have become
an increasing problem in the HIV clinic. Moreover,
concerns are enhanced by the association between select
ARV agents and insulin resistance, dyslipidemia and fat
maldistribution, along with case reports of premature
cardiovascular disease [1]. While there is little evidence
clearly demonstrating an association between any
specific drug and visceral adiposity, lipoatrophy does
appear to be a HIV-1-specific condition primarily linked
to the use of thymidine analogues such as zidovudine
and stavudine [2]. Similarly, it is now clear that lipid
abnormalities have been seen with select NRTIs, non-
NRTIs, and PIs. In fact, there are specific guidelines for
the management of dyslipidemia in HIV-1-infected
individuals [3,4].
While several studies have reported a relationship
between ARV use and cardiovascular events, the D:A:D
(Data Collection on Adverse Events of Anti-HIV Drugs)
cohort is the largest longitudinal study specifically
designed to address this question. This study has
provided the best evidence that there is an independent
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therapy and cardiovascular events [5], with most of the
effect initially being linked to the use of PIs [6]. More
recent analyses of this cohort have addressed the
relationship between NRTI use and cardiovascular
disease. Here they showed that the recent use of abacavir
and, to a lesser extent, didanosine was associated with
increased risk of cardiac events when compared to
regimens that did not use these drugs [7]. Notably the
absolute risk was small for all groups and was most
prominent amongst those with other cardiovascular risk
factors. A follow-up analysis presented at the 16
th
Conference on Retroviruses and Opportunistic Infec-
tions showed that there was also an independent
association between cardiovascular events and the use
of lopinavir/ritonavir and indinavir, while no such
relationship was seen with tenofovir disoproxil fumarate
(tenofovir DF) or the non-NRTIs efavirenz and nevir-
apine [8]. It is important to note that while cohorts can
include large numbers of longitudinally followed
patients, they are not randomized controlled trials and
therefore have numerous limitations. That being said, a
similar association between abacavir use and cardiovas-
cular events was recently reported from the SMART
(Strategies for Management of Anti-Retroviral Therapy)
study [9] and a case control study of patients in the ANRS
(National Agency for AIDS Research) French Hospital
cohort [10]. Nevertheless, questions remain since there
has been no definitive biological explanation given for
these findings and other studies have not demonstrated
such associations [11].
Intriguing data have recently emerged to suggest a
relationship between ongoing viremia and cardiovascu-
lar disease [12]. Data from the SMART study, designed
to assess whether treatment interruption in those with
higher levels of CD4
+ T cells could minimize some of the
toxicity associated with ARV therapy, actually showed
overall increased risk of several non-AIDS events,
including cardiovascular, renal and hepatic disease,
amongst those that interrupted treatment [13]. Further
analyses from the SMART study have demonstrated that
markers of inflammation, such as interleukin-6 (IL-6),
and coagulation, such as D-dimers, are increased in those
off ARV therapy, all of these markers having been shown
in other populations to be associated with increased risk
of cardiovascular events [14]. These findings have been
corroborated in another cohort of patients undergoing
ARV treatment interruption [15]. Stored samples from
the SMART study have further been used to link these
changes in markers of inflammation with abacavir use.
In a cross-sectional analysis of patients either on or off
abacavir at baseline, the investigators showed increased
levels of high sensitivity C-reactive protein and IL-6 in
those on abacavir compared to those not taking this drug
[9]. However, another study showed different results,
demonstrating that related markers declined to a similar
extent in both arms in a randomized controlled trial
comparing tenofovir DF/emtricitabine to abacavir/lami-
vudine [16]. These differences may reflect the difficulty
in observing a potentially modest relationship between
select ARV agents and markers of inflammation in the
face of the overwhelming influence that suppressing
plasma HIV-1 RNA has on these same measures. While
results are inconclusive, other potential markers asso-
ciated with increased cardiovascular disease have also
been evaluated as explanations for the possible relation-
ship between select ARV agents and cardiovascular
events, such as endothelial function [17] and platelet
aggregation [18]. While there remains considerable
uncertainty as to how these various data sets should be
interpreted, these observations have led to new research
exploring the relationship between HIV-1 replication
and potential pathogenic mechanisms for select end-
organ events.
Renal disease
Renal disease is common amongst those with HIV-1
infection and is often multifactorial; possible factors
include HIV-1-associated nephropathy and co-morbid
conditions such as diabetes mellitus and hypertension,
as well as co-infection with hepatitis B and C [19].
Certain ARV drugs have also been associated with
nephrotoxicity, such as indinavir, a drug rarely used in
the current era that frequently caused nephrolithiasis and
occasionally interstitial nephritis. In addition, tenofovir
DF has been linked to the development of proximalrenal
tubular dysfunction. It is clearly recommended that
routine monitoring of renal function should occur in all
HIV-1-infected patients, with particular attention given
to those with co-morbid conditions or taking nephro-
toxic drugs [20].
One recent study attempted to define the relationship
between renal function, tenofovir DF use, and the degree
of plasma HIV-1 RNA suppression. This was a relatively
small cohort study showing that those with complete
viral suppression on a tenofovir DF-containing regimen
actually experienced an increase in glomerular filtration
rate. In contrast, there was a small but significant decline
in renal function amongst those on tenofovir DF that
did not achieve full virologic suppression. The authors
hypothesize that ongoing viremia, and perhaps the
associated increase in inflammation, could be contribut-
ing to these adverse outcomes [21]. Other studies have
shown a similar relationship between HIV-1 replication
and progression of renal disease [22,23].
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The overwhelming burden of hepatic disease in HIV-
1-infected individuals is related to co-infection with
hepatitis B and C [24]. HIV-1 and hepatitis co-infection
treatment guidelines provide detailed information about
relevant interactions between these chronic viral infec-
tions and how co-infection influences the management
of each pathogen [25]. There is also an increased risk of
hepatic steatosis that may be associated with hyperlipi-
demia, insulin resistance and select ARV agents [26].
Several ARVs have also been shown to result in
hepatotoxicity, the strongest links being with high-dose
ritonavir, rarely used in the current treatment era, and
tipranavir and nevirapine, the latter being in association
with immunologic reactions that can be minimized by
avoiding use in men with >400 CD4
+ T-cells/mL and
women with >250 CD4
+ T cells/mL [27]. There have been
a few case reports of significant hepatotoxicity with the
CCR5 antagonist maraviroc, but this has not been clearly
seen in the pivotal randomized controlled trials [28].
While there was some increased risk of hepatotoxicity
associated with treatment interruption in the SMART
study [13], there are currently much fewer data linking
ongoing HIV-1 replication to liver abnormalities than
what has been described for cardiovascular and renal
disease.
Implications for clinical practice
There are currently many ARV options available to
patients living with HIV-1 disease. A thorough under-
standing of the relationship between different drugs and
various adverse events is critical to the optimal manage-
ment of such patients. The first step towards safely using
any medication is to know what conditions any given
individual is predisposed to, to understand the safety
profile of each drug, and to monitor for adverse events.
In the case of cardiovascular disease it is important to
emphasize efforts to modify known risk factors and to
monitor and manage dyslipidemia [4]. When lipid
abnormalities are present, clinicians should be aware of
how different medications may be contributing to these
problems and should consider changes in therapy when
appropriate. The emerging data linking select drugs to
cardiovascular disease, while not definitive, should also
be considered when making any clinical decision,
particularly in those with other risk factors. Similar
considerations apply to underlying renal disease, where
control of traditional risk factors such as diabetes
mellitus and hypertension should be prioritized along
with careful monitoring and avoidance of nephrotoxic
drugs in those at greatest risk. With regards to liver
disease, the best strategy is to diligently screen for
hepatitis B and C co-infection, minimize use of
hepatotoxic agents and to provide immunization against
viral hepatitis when appropriate. In addition, all patients
should be carefully monitored for liver disease, with a
particular focus on those taking hepatotoxic agents and
who are hepatitis B and/or C co-infected.
The recent data linking ongoing HIV-1 replication with
cardiovascular disease, and possibly renal disease, are
provocative, and the association remains an area of
increasing investigation. Clinicians should be aware of
these studies, their potential implications with regards to
the use of ARV therapy, and how these findings might
support the earlier initiation of treatment in a given
individual. However, this needs to be balanced by the
fact that the studies remain preliminary and the results
thus far have been mostly hypothesis generating.
Furthermore, decisions regarding the timing of treatment
must be made in the context of the specific patient to be
treated as well as the overall costs and known risks
associated with the use of ARV therapy.
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